EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer

Akiharu Kimura, Akihiko Sano, Nobuhiro Nakazawa, Yuji Kumakura, Toshiki Yamashita, Naritaka Tanaka, Kana Saito, Kyoichi Ogata, Kengo Kasuga, Kenji Nakazato, Daisuke Yoshinari, Hisashi Shimizu und 7 weitere

Oncology · 2026

DOI: 10.1159/000550345 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology, 2026. Verfasst von Akiharu Kimura und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan. Hauptthemen laut MEDLINE: Nivolumab, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Nivolumab combined with chemotherapy has been approved as the first-line treatment for HER2-negative, unresectable, advanced, or recurrent gastric cancer. Patients aged ≥75 years have impaired organ function and comorbidities that increase the risk of adverse events, including immune-related adverse events more often than younger patients, potentially limiting the continuation of treatment. In this multicenter study, we aimed to evaluate the safety and efficacy of first-line nivolumab chemotherapy in older patients.

Methods

We retrospectively analyzed data from 103 patients treated with first-line nivolumab combination chemotherapy for unresectable, advanced, or recurrent gastric cancer at 12 institutions between November 2021 and January 2023. The participants were divided into groups A (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansFemaleAgedRetrospective StudiesMaleAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

Aged patientsAntineoplastic combined chemotherapy protocolsGastric neoplasmsMulticenter studyNivolumab

Substanzen

Nivolumab

Autor:innen und Institutionen

  • Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan.
  • Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan, ak_sano@gunma-u.ac.jp.
  • Department of Surgery, Tonechuo Hospital, Numata, Japan.
  • Department of Surgery, Subaru Health Insurance Society Ota Memorial Hospital, Ota, Japan.
  • Department of Surgery, Japanese Red Cross Haramachi Hospital, Agatsuma, Japan.
  • Department of Surgery, Japan Community Healthcare Organization Gunma Central Hospital, Maebashi, Japan.

Zitieren

APA

Kimura, A., Sano, A., Nakazawa, N., Kumakura, Y., Yamashita, T., Tanaka, N., Saito, K., Ogata, K., Kasuga, K., Nakazato, K., Yoshinari, D., Shimizu, H., Ubukata, Y., Hosaka, H., Okada, T., Shiraishi, T., Sakai, M., Shirabe, K., & Saeki, H. (2026). Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer. Oncology. https://doi.org/10.1159/000550345

Vancouver

Kimura A, Sano A, Nakazawa N, Kumakura Y, Yamashita T, Tanaka N, et al. Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer. Oncology. 2026. doi:10.1159/000550345

BibTeX
@article{Kimura2026,
  author = {Kimura, Akiharu and Sano, Akihiko and Nakazawa, Nobuhiro and Kumakura, Yuji and Yamashita, Toshiki and Tanaka, Naritaka and Saito, Kana and Ogata, Kyoichi and Kasuga, Kengo and Nakazato, Kenji and Yoshinari, Daisuke and Shimizu, Hisashi and Ubukata, Yasunari and Hosaka, Hisashi and Okada, Takuhisa and Shiraishi, Takuya and Sakai, Makoto and Shirabe, Ken and Saeki, Hiroshi},
  title = {Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer},
  journal = {Oncology},
  year = {2026},
  doi = {10.1159/000550345}
}
Kostenlos starten →